Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 370 participants.

Also called NCT03713684

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 370 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03713684
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, China, South Korea (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03713684. Randomized; quadruple masking; primary purpose treatment. Start 2018-11-09 (actual); primary completion 2020-11-20 (actual). Results posted on 2021-12-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
Acronym
AMPLITUDE-L
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Efpeglenatide SAR439977
Intervention (Drug)
Placebo
Intervention (Drug)
Background therapy
Lead sponsor
Sanofi (class: industry)
Collaborator
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct03713684
Content hash
e1e8dcc71474ac5360306616bc923f80af9338c4ebb05be059133a02a7c70090